Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Receivables: 2021-2025

Historic Receivables for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $51.7 million.

  • Kiniksa Pharmaceuticals International's Receivables rose 107.90% to $51.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $165.4 million, marking a year-over-year increase of 100.29%. This contributed to the annual value of $41.7 million for FY2024, which is 96.20% up from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Receivables stood at $51.7 million for Q3 2025, which was up 62.15% from $31.9 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's 5-year Receivables high stood at $51.7 million for Q3 2025, and its period low was $2.6 million during Q2 2021.
  • Moreover, its 3-year median value for Receivables was $24.6 million (2023), whereas its average is $25.7 million.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Receivables tumbled by 74.78% in 2023, and later skyrocketed by 718.41% in 2024.
  • Kiniksa Pharmaceuticals International's Receivables (Quarterly) stood at $4.0 million in 2021, then skyrocketed by 409.81% to $20.3 million in 2022, then increased by 4.68% to $21.3 million in 2023, then spiked by 96.20% to $41.7 million in 2024, then spiked by 107.90% to $51.7 million in 2025.
  • Its Receivables stands at $51.7 million for Q3 2025, versus $31.9 million for Q2 2025 and $40.1 million for Q1 2025.